Hypertension, ISSN 0194-911X, 08/2012, Volume 60, Issue 2, pp. 387 - 395
In angiotensin type 1 receptor–blocked rats, renal interstitial (RI) administration of des-aspartyl-angiotensin II (Ang III) but not angiotensin II induces...
angiotensin | kidney | natriuresis | sodium | cGMP | receptor | SYSTEM | AT RECEPTOR | RAT-KIDNEY | CONVERSION | INHIBITION | PERIPHERAL VASCULAR DISEASE | HYPERTENSION | Angiotensin III - pharmacology | Natriuresis - physiology | Angiotensin II - pharmacology | Tetrazoles - pharmacology | Natriuresis - drug effects | Rats | Receptor, Angiotensin, Type 2 - drug effects | Peptide Fragments - pharmacology | Imidazoles - pharmacology | Angiotensin II Type 1 Receptor Blockers - pharmacology | Rats, Sprague-Dawley | Angiotensin II Type 2 Receptor Blockers - pharmacology | Animals | Receptor, Angiotensin, Type 2 - metabolism | Kidney Tubules, Proximal - metabolism | Benzimidazoles - pharmacology | Female | Models, Animal | Angiotensin I - pharmacology | Pyridines - pharmacology | Kidney Tubules, Proximal - drug effects
angiotensin | kidney | natriuresis | sodium | cGMP | receptor | SYSTEM | AT RECEPTOR | RAT-KIDNEY | CONVERSION | INHIBITION | PERIPHERAL VASCULAR DISEASE | HYPERTENSION | Angiotensin III - pharmacology | Natriuresis - physiology | Angiotensin II - pharmacology | Tetrazoles - pharmacology | Natriuresis - drug effects | Rats | Receptor, Angiotensin, Type 2 - drug effects | Peptide Fragments - pharmacology | Imidazoles - pharmacology | Angiotensin II Type 1 Receptor Blockers - pharmacology | Rats, Sprague-Dawley | Angiotensin II Type 2 Receptor Blockers - pharmacology | Animals | Receptor, Angiotensin, Type 2 - metabolism | Kidney Tubules, Proximal - metabolism | Benzimidazoles - pharmacology | Female | Models, Animal | Angiotensin I - pharmacology | Pyridines - pharmacology | Kidney Tubules, Proximal - drug effects
Journal Article
Hypertension, ISSN 0194-911X, 03/2006, Volume 47, Issue 3, Part 2 Suppl, pp. 537 - 544
Whereas angiotensin (Ang) II is the major effector peptide of the renin–angiotensin system, its metabolite, des-aspartyl-Ang II (Ang III), may also have...
Natriuresis | Sodium | Angiotensin | Receptors, angiotensin II | SYSTEM | sodium | natriuresis | CELLS | AT RECEPTOR | ROLES | angiotensin | receptors, angiotensin II | PERIPHERAL VASCULAR DISEASE | KIDNEY | BLOOD-PRESSURE | MICE LACKING | Angiotensin III - pharmacology | Natriuresis - physiology | Tetrazoles - pharmacology | Natriuresis - drug effects | Sodium Chloride, Dietary - pharmacology | Receptor, Angiotensin, Type 2 - physiology | Sodium Chloride, Dietary - administration & dosage | Rats | Receptor, Angiotensin, Type 2 - drug effects | Imidazoles - pharmacology | Angiotensin II Type 1 Receptor Blockers - pharmacology | Rats, Sprague-Dawley | Dose-Response Relationship, Drug | Kidney - metabolism | Animals | Nephrectomy | Angiotensin III - physiology | Angiotensin II Type 2 Receptor Blockers | Benzimidazoles - pharmacology | Pyridines - pharmacology | Drug Combinations
Natriuresis | Sodium | Angiotensin | Receptors, angiotensin II | SYSTEM | sodium | natriuresis | CELLS | AT RECEPTOR | ROLES | angiotensin | receptors, angiotensin II | PERIPHERAL VASCULAR DISEASE | KIDNEY | BLOOD-PRESSURE | MICE LACKING | Angiotensin III - pharmacology | Natriuresis - physiology | Tetrazoles - pharmacology | Natriuresis - drug effects | Sodium Chloride, Dietary - pharmacology | Receptor, Angiotensin, Type 2 - physiology | Sodium Chloride, Dietary - administration & dosage | Rats | Receptor, Angiotensin, Type 2 - drug effects | Imidazoles - pharmacology | Angiotensin II Type 1 Receptor Blockers - pharmacology | Rats, Sprague-Dawley | Dose-Response Relationship, Drug | Kidney - metabolism | Animals | Nephrectomy | Angiotensin III - physiology | Angiotensin II Type 2 Receptor Blockers | Benzimidazoles - pharmacology | Pyridines - pharmacology | Drug Combinations
Journal Article
Peptides, ISSN 0196-9781, 04/2013, Volume 42, pp. 131 - 137
► Angiotensin III stimulated high stretch-inducedANP secretion. ► These effects were mediated through AT2 receptor/PI3K/Akt/NO/PKG pathway. ► Intravenous...
Hypertension | Angiotensin III | Receptor | Atrial natriuretic peptide | Angiotensin II | Hypertrophy | Atrial stretch | MYOCYTES IN-VITRO | SYSTEM | TRANSLOCATION | ATRIAL-NATRIURETIC-PEPTIDE | RAT | BIOCHEMISTRY & MOLECULAR BIOLOGY | PERFUSED RABBIT ATRIA | VASOPRESSIN RELEASE | EXTRACELLULAR FLUID | ROLES | PHARMACOLOGY & PHARMACY | INHIBITORS | Angiotensin II - administration & dosage | Heart Atria - drug effects | Myocardial Contraction - physiology | Myocardial Contraction - drug effects | Male | Angiotensin II Type 1 Receptor Blockers - pharmacology | Atrial Natriuretic Factor - blood | Angiotensin II Type 2 Receptor Blockers - pharmacology | Dose-Response Relationship, Drug | Angiotensin III - administration & dosage | Angiotensin III - pharmacology | Angiotensin II - pharmacology | Losartan - pharmacology | Rats | Imidazoles - pharmacology | Rats, Sprague-Dawley | Heart Atria - metabolism | Animals | Receptor, Angiotensin, Type 2 - metabolism | Signal Transduction - drug effects | Perfusion | Pyridines - pharmacology | Infusions, Intravenous | In Vitro Techniques | Atrial Natriuretic Factor - secretion | Physiological aspects | Angiotensin | Natriuretic peptides
Hypertension | Angiotensin III | Receptor | Atrial natriuretic peptide | Angiotensin II | Hypertrophy | Atrial stretch | MYOCYTES IN-VITRO | SYSTEM | TRANSLOCATION | ATRIAL-NATRIURETIC-PEPTIDE | RAT | BIOCHEMISTRY & MOLECULAR BIOLOGY | PERFUSED RABBIT ATRIA | VASOPRESSIN RELEASE | EXTRACELLULAR FLUID | ROLES | PHARMACOLOGY & PHARMACY | INHIBITORS | Angiotensin II - administration & dosage | Heart Atria - drug effects | Myocardial Contraction - physiology | Myocardial Contraction - drug effects | Male | Angiotensin II Type 1 Receptor Blockers - pharmacology | Atrial Natriuretic Factor - blood | Angiotensin II Type 2 Receptor Blockers - pharmacology | Dose-Response Relationship, Drug | Angiotensin III - administration & dosage | Angiotensin III - pharmacology | Angiotensin II - pharmacology | Losartan - pharmacology | Rats | Imidazoles - pharmacology | Rats, Sprague-Dawley | Heart Atria - metabolism | Animals | Receptor, Angiotensin, Type 2 - metabolism | Signal Transduction - drug effects | Perfusion | Pyridines - pharmacology | Infusions, Intravenous | In Vitro Techniques | Atrial Natriuretic Factor - secretion | Physiological aspects | Angiotensin | Natriuretic peptides
Journal Article
Clinical science (London, England : 1979), ISSN 0143-5221, 2015, Volume 129, Issue 6, pp. 505 - 513
We have previously shown that individual β-amino acid substitution in angiotensin (Ang) II reduced Ang II type 1 receptor (AT1R) but not Ang II type 2 receptor...
blood pressure | angiotensin II type 2 (AT2) receptor | receptor | vasorelaxation | angiotensin III | Angiotensin II type 2 (AT | β-amino acid substitutions | Receptors, Angiotensin - metabolism | Isometric Contraction - drug effects | Angiotensin III - blood | Humans | Hypertension - drug therapy | Male | Muscle, Smooth, Vascular - physiopathology | Angiotensin II Type 2 Receptor Blockers - pharmacology | Tetrazoles - metabolism | HEK293 Cells | Inhibitory Concentration 50 | Receptors, Angiotensin - chemistry | Aorta, Thoracic - drug effects | Muscle, Smooth, Vascular - drug effects | Binding, Competitive | Vasoconstrictor Agents - pharmacology | Amino Acid Sequence | Angiotensin III - pharmacology | Angiotensin III - analogs & derivatives | Drug Stability | Rats | Imidazoles - pharmacology | Aorta, Thoracic - physiopathology | Animals | Analysis of Variance | Benzimidazoles - metabolism | Mice | Pyridines - pharmacology | Vasodilation - drug effects | In Vitro Techniques
blood pressure | angiotensin II type 2 (AT2) receptor | receptor | vasorelaxation | angiotensin III | Angiotensin II type 2 (AT | β-amino acid substitutions | Receptors, Angiotensin - metabolism | Isometric Contraction - drug effects | Angiotensin III - blood | Humans | Hypertension - drug therapy | Male | Muscle, Smooth, Vascular - physiopathology | Angiotensin II Type 2 Receptor Blockers - pharmacology | Tetrazoles - metabolism | HEK293 Cells | Inhibitory Concentration 50 | Receptors, Angiotensin - chemistry | Aorta, Thoracic - drug effects | Muscle, Smooth, Vascular - drug effects | Binding, Competitive | Vasoconstrictor Agents - pharmacology | Amino Acid Sequence | Angiotensin III - pharmacology | Angiotensin III - analogs & derivatives | Drug Stability | Rats | Imidazoles - pharmacology | Aorta, Thoracic - physiopathology | Animals | Analysis of Variance | Benzimidazoles - metabolism | Mice | Pyridines - pharmacology | Vasodilation - drug effects | In Vitro Techniques
Journal Article
Peptides, ISSN 0196-9781, 10/2012, Volume 37, Issue 2, pp. 200 - 206
► Ang III and Ang II can regulate cell migration and proliferation in prostate cancer lines. ► The biological properties of angiotensin are associated with the...
Cell proliferation | Angiotensin III | Angiotensin II | Prostate cancer | AT1 | Cell migration | AT2 | SYSTEM | ANTIPROLIFERATIVE ACTIVITY | OLD | BIOCHEMISTRY & MOLECULAR BIOLOGY | TYPE-1 RECEPTOR | BREAST | PEPTIDES | GROWTH | ENDOCRINOLOGY & METABOLISM | PHARMACOLOGY & PHARMACY | EXPRESSION | BLOCKER | Angiotensin III - antagonists & inhibitors | Angiotensin III - pharmacology | Prostatic Neoplasms - pathology | Angiotensin II - pharmacology | Antineoplastic Agents - antagonists & inhibitors | Humans | Losartan - pharmacology | Male | Imidazoles - pharmacology | Structure-Activity Relationship | Dose-Response Relationship, Drug | Cell Movement - drug effects | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Pyridines - pharmacology | Prostatic Neoplasms - drug therapy | Drug Screening Assays, Antitumor | Metastasis | Analysis | Cells | Angiotensin
Cell proliferation | Angiotensin III | Angiotensin II | Prostate cancer | AT1 | Cell migration | AT2 | SYSTEM | ANTIPROLIFERATIVE ACTIVITY | OLD | BIOCHEMISTRY & MOLECULAR BIOLOGY | TYPE-1 RECEPTOR | BREAST | PEPTIDES | GROWTH | ENDOCRINOLOGY & METABOLISM | PHARMACOLOGY & PHARMACY | EXPRESSION | BLOCKER | Angiotensin III - antagonists & inhibitors | Angiotensin III - pharmacology | Prostatic Neoplasms - pathology | Angiotensin II - pharmacology | Antineoplastic Agents - antagonists & inhibitors | Humans | Losartan - pharmacology | Male | Imidazoles - pharmacology | Structure-Activity Relationship | Dose-Response Relationship, Drug | Cell Movement - drug effects | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Cell Proliferation - drug effects | Pyridines - pharmacology | Prostatic Neoplasms - drug therapy | Drug Screening Assays, Antitumor | Metastasis | Analysis | Cells | Angiotensin
Journal Article
Hypertension, ISSN 0194-911X, 02/2009, Volume 53, Issue 2, Part 2 Suppl, pp. 338 - 343
In Sprague-Dawley rats, renal angiotensin (Ang) type 2 receptors (AT2Rs) mediate natriuresis in response to renal interstitial (RI) D1-like receptor...
SYSTEM | natriuresis | RECRUITMENT | translocation | TRAFFICKING | angiotensin III | PRESSURE REGULATION | PLASMA-MEMBRANE | AT receptor | sodium | CONTRACTION | PERIPHERAL VASCULAR DISEASE | KIDNEY | REABSORPTION | Tetrazoles - pharmacology | Rats, Inbred WKY | Angiotensin II Type 1 Receptor Blockers - pharmacology | Hypertension - etiology | Sodium - urine | Female | Blood Pressure - drug effects | Cell Membrane - metabolism | Receptor, Angiotensin, Type 1 - drug effects | Cell Membrane - drug effects | Disease Models, Animal | Rats, Inbred SHR | Angiotensin III - pharmacology | Natriuresis - drug effects | Rats | Imidazoles - pharmacology | Hypertension - metabolism | Animals | Receptor, Angiotensin, Type 2 - metabolism | Receptor, Angiotensin, Type 1 - metabolism | Kidney Tubules, Proximal - metabolism | Angiotensin II Type 2 Receptor Blockers | Benzimidazoles - pharmacology | Pyridines - pharmacology | Kidney Tubules, Proximal - drug effects
SYSTEM | natriuresis | RECRUITMENT | translocation | TRAFFICKING | angiotensin III | PRESSURE REGULATION | PLASMA-MEMBRANE | AT receptor | sodium | CONTRACTION | PERIPHERAL VASCULAR DISEASE | KIDNEY | REABSORPTION | Tetrazoles - pharmacology | Rats, Inbred WKY | Angiotensin II Type 1 Receptor Blockers - pharmacology | Hypertension - etiology | Sodium - urine | Female | Blood Pressure - drug effects | Cell Membrane - metabolism | Receptor, Angiotensin, Type 1 - drug effects | Cell Membrane - drug effects | Disease Models, Animal | Rats, Inbred SHR | Angiotensin III - pharmacology | Natriuresis - drug effects | Rats | Imidazoles - pharmacology | Hypertension - metabolism | Animals | Receptor, Angiotensin, Type 2 - metabolism | Receptor, Angiotensin, Type 1 - metabolism | Kidney Tubules, Proximal - metabolism | Angiotensin II Type 2 Receptor Blockers | Benzimidazoles - pharmacology | Pyridines - pharmacology | Kidney Tubules, Proximal - drug effects
Journal Article
Hypertension, ISSN 0194-911X, 02/2010, Volume 55, Issue 2, Part 2 Suppl, pp. 516 - 522
Because angiotensin (Ang) metabolites mediate functions independent of Ang II, we investigated their effects on coronary flow in spontaneously hypertensive...
Angiotensin (1-7) | Spontaneously hypertensive rat | Angiotensin III | Wistar rat | AT2 receptor | SYSTEM | ACTIVATION | MYOCARDIAL-INFARCTION | RESISTANCE ARTERIES | angiotensin III | spontaneously hypertensive rat | AT receptor | BLOOD-PRESSURE | CONSCIOUS RATS | NITRIC-OXIDE | PERIPHERAL VASCULAR DISEASE | VASOCONSTRICTION | angiotensin (1-7) | Tetrazoles - pharmacology | Coronary Circulation - physiology | Iliac Artery - drug effects | Rats, Wistar | Male | Reference Values | Aorta, Abdominal - drug effects | Vasoconstriction - physiology | Biphenyl Compounds - pharmacology | Iliac Artery - metabolism | Vasodilation - physiology | Aorta, Abdominal - metabolism | Disease Models, Animal | Rats, Inbred SHR | Angiotensin III - pharmacology | Angiotensin II - pharmacology | Angiotensin II - metabolism | Probability | Rats | Imidazoles - pharmacology | Random Allocation | Vasoconstriction - drug effects | Angiotensin III - metabolism | Animals | Receptor, Angiotensin, Type 2 - metabolism | Analysis of Variance | Pyridines - pharmacology | Coronary Circulation - drug effects | Vasodilation - drug effects
Angiotensin (1-7) | Spontaneously hypertensive rat | Angiotensin III | Wistar rat | AT2 receptor | SYSTEM | ACTIVATION | MYOCARDIAL-INFARCTION | RESISTANCE ARTERIES | angiotensin III | spontaneously hypertensive rat | AT receptor | BLOOD-PRESSURE | CONSCIOUS RATS | NITRIC-OXIDE | PERIPHERAL VASCULAR DISEASE | VASOCONSTRICTION | angiotensin (1-7) | Tetrazoles - pharmacology | Coronary Circulation - physiology | Iliac Artery - drug effects | Rats, Wistar | Male | Reference Values | Aorta, Abdominal - drug effects | Vasoconstriction - physiology | Biphenyl Compounds - pharmacology | Iliac Artery - metabolism | Vasodilation - physiology | Aorta, Abdominal - metabolism | Disease Models, Animal | Rats, Inbred SHR | Angiotensin III - pharmacology | Angiotensin II - pharmacology | Angiotensin II - metabolism | Probability | Rats | Imidazoles - pharmacology | Random Allocation | Vasoconstriction - drug effects | Angiotensin III - metabolism | Animals | Receptor, Angiotensin, Type 2 - metabolism | Analysis of Variance | Pyridines - pharmacology | Coronary Circulation - drug effects | Vasodilation - drug effects
Journal Article
Hypertension, ISSN 0194-911X, 03/2007, Volume 49, Issue 3, Part 2 Suppl, pp. 625 - 630
The renal angiotensin angiotensin type 2 receptor has been shown to mediate natriuresis, and angiotensin III, not angiotensin II, may be the preferential...
receptor | Natriuresis | Angiotensin III | Sodium | Angiotensin | natriuresis | CONVERTING ENZYME | CELLS | LOCALIZATION | angiotensin III | MECHANISMS | AT receptor | VASOPRESSIN RELEASE | RENIN SYSTEM | sodium | DISEASES | angiotensin | PERIPHERAL VASCULAR DISEASE | KIDNEY | HYPERTENSION | EXPRESSION | Natriuretic Agents - pharmacology | Angiotensin III - pharmacology | Natriuresis - drug effects | CD13 Antigens - antagonists & inhibitors | Enzyme Inhibitors - pharmacology | Rats | Receptors, Angiotensin - drug effects | Methionine - pharmacology | Rats, Sprague-Dawley | Animals | Benzimidazoles - administration & dosage | Methionine - analogs & derivatives | Sodium - urine | Tetrazoles - administration & dosage | Models, Animal | Angiotensin II Type 1 Receptor Blockers - administration & dosage
receptor | Natriuresis | Angiotensin III | Sodium | Angiotensin | natriuresis | CONVERTING ENZYME | CELLS | LOCALIZATION | angiotensin III | MECHANISMS | AT receptor | VASOPRESSIN RELEASE | RENIN SYSTEM | sodium | DISEASES | angiotensin | PERIPHERAL VASCULAR DISEASE | KIDNEY | HYPERTENSION | EXPRESSION | Natriuretic Agents - pharmacology | Angiotensin III - pharmacology | Natriuresis - drug effects | CD13 Antigens - antagonists & inhibitors | Enzyme Inhibitors - pharmacology | Rats | Receptors, Angiotensin - drug effects | Methionine - pharmacology | Rats, Sprague-Dawley | Animals | Benzimidazoles - administration & dosage | Methionine - analogs & derivatives | Sodium - urine | Tetrazoles - administration & dosage | Models, Animal | Angiotensin II Type 1 Receptor Blockers - administration & dosage
Journal Article
Endocrinology, ISSN 0013-7227, 01/2013, Volume 154, Issue 1, pp. 214 - 221
Aldosterone is synthesized in the zona glomerulosa of the adrenal cortex under primary regulation by the renin-angiotensin system. Angiotensin II (A-II) acts...
CONSCIOUS DOGS | SIGNALING PATHWAYS | RECEPTOR SUBTYPES | RAT | ZONA GLOMERULOSA | ENDOCRINOLOGY & METABOLISM | DOUBLE BLOCKADE | ALDOSTERONE PRODUCTION | GLOMERULOSA CELLS | EXPRESSION | RENIN SYSTEM | Angiotensin III - pharmacology | Cell Line | Angiotensin II - pharmacology | Angiotensin II - metabolism | Humans | Adrenal Cortex - metabolism | Hydrocortisone - secretion | Losartan - pharmacology | Aldosterone - secretion | Steroid 11-beta-Hydroxylase - genetics | Angiotensin II Type 1 Receptor Blockers - pharmacology | Angiotensin III - metabolism | Steroid 17-alpha-Hydroxylase - genetics | Adrenal Cortex - drug effects | 3-Hydroxysteroid Dehydrogenases - genetics | Cytochrome P-450 CYP11B2 - genetics | Index Medicus | Abridged Index Medicus | 500 | Glucocorticoids-CRH-ACTH-Adrenal | 300
CONSCIOUS DOGS | SIGNALING PATHWAYS | RECEPTOR SUBTYPES | RAT | ZONA GLOMERULOSA | ENDOCRINOLOGY & METABOLISM | DOUBLE BLOCKADE | ALDOSTERONE PRODUCTION | GLOMERULOSA CELLS | EXPRESSION | RENIN SYSTEM | Angiotensin III - pharmacology | Cell Line | Angiotensin II - pharmacology | Angiotensin II - metabolism | Humans | Adrenal Cortex - metabolism | Hydrocortisone - secretion | Losartan - pharmacology | Aldosterone - secretion | Steroid 11-beta-Hydroxylase - genetics | Angiotensin II Type 1 Receptor Blockers - pharmacology | Angiotensin III - metabolism | Steroid 17-alpha-Hydroxylase - genetics | Adrenal Cortex - drug effects | 3-Hydroxysteroid Dehydrogenases - genetics | Cytochrome P-450 CYP11B2 - genetics | Index Medicus | Abridged Index Medicus | 500 | Glucocorticoids-CRH-ACTH-Adrenal | 300
Journal Article
Endocrinology, ISSN 0013-7227, 04/2011, Volume 152, Issue 4, pp. 1582 - 1588
As Ang III stimulates adrenal aldosterone secretion partially via AT2R but not AT1R, Ang III and AT2R may be involved in “aldosterone breakthrough.”...
SYSTEM | INHIBITION | ANTAGONIST | AT RECEPTOR | BREAKTHROUGH | ENDOCRINOLOGY & METABOLISM | RATS | DOUBLE BLOCKADE | CARDIAC FIBROSIS | EPLERENONE | GENERATING ENZYMES | Immunohistochemistry | Angiotensin III - pharmacology | Receptor, Angiotensin, Type 2 - genetics | Zona Glomerulosa - drug effects | Aldosterone - secretion | Rats | Male | Zona Glomerulosa - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Rats, Sprague-Dawley | Aldosterone - metabolism | Receptor, Angiotensin, Type 1 - genetics | Animals | Receptor, Angiotensin, Type 2 - metabolism | Receptor, Angiotensin, Type 1 - metabolism
SYSTEM | INHIBITION | ANTAGONIST | AT RECEPTOR | BREAKTHROUGH | ENDOCRINOLOGY & METABOLISM | RATS | DOUBLE BLOCKADE | CARDIAC FIBROSIS | EPLERENONE | GENERATING ENZYMES | Immunohistochemistry | Angiotensin III - pharmacology | Receptor, Angiotensin, Type 2 - genetics | Zona Glomerulosa - drug effects | Aldosterone - secretion | Rats | Male | Zona Glomerulosa - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Rats, Sprague-Dawley | Aldosterone - metabolism | Receptor, Angiotensin, Type 1 - genetics | Animals | Receptor, Angiotensin, Type 2 - metabolism | Receptor, Angiotensin, Type 1 - metabolism
Journal Article
Neuroscience, ISSN 0306-4522, 2009, Volume 164, Issue 3, pp. 1263 - 1273
Abstract Endogenous angiotensin (Ang) II and/or an Ang II-derived peptide, acting on Ang type 1 (AT1 ) and Ang type 2 (AT2 ) receptors, can carry out part of...
Neurology | CGP 42,112A | antinociception | divalinal-angiotensin IV | tail flick and allodynia models | Losartan | renin–angiotensin system | renin-angiotensin system | CONVERTING ENZYME | AMINOPEPTIDASE AMINOPEPTIDASE-A | NUCLEUS-RETICULARIS GIGANTOCELLULARIS | SYSTEM PEPTIDES | NEUROSCIENCES | VASOPRESSIN RELEASE | RAT MODEL | CGP 42 | SMOOTH-MUSCLE | RECEPTOR SUBTYPES | ANTERIOR PRETECTAL NUCLEUS | 112A | INCISIONAL PAIN | Receptors, Angiotensin - metabolism | Analgesics - pharmacology | Pain Threshold - physiology | Rats, Wistar | Angiotensin Receptor Antagonists | Periaqueductal Gray - drug effects | Analgesics - metabolism | Male | Pain - metabolism | Efferent Pathways - drug effects | Neural Inhibition - physiology | Glutamyl Aminopeptidase - biosynthesis | Pain - drug therapy | Pain Threshold - drug effects | Disease Models, Animal | Angiotensin III - pharmacology | Angiotensin II - pharmacology | Microinjections | Losartan - pharmacology | Rats | Periaqueductal Gray - metabolism | Angiotensin III - metabolism | Efferent Pathways - metabolism | Peptides - pharmacology | Animals | Pain - physiopathology | Drug Interactions - physiology | Nociceptors - metabolism | Oligopeptides - pharmacology | Pain Measurement | Neural Inhibition - drug effects | Nociceptors - drug effects
Neurology | CGP 42,112A | antinociception | divalinal-angiotensin IV | tail flick and allodynia models | Losartan | renin–angiotensin system | renin-angiotensin system | CONVERTING ENZYME | AMINOPEPTIDASE AMINOPEPTIDASE-A | NUCLEUS-RETICULARIS GIGANTOCELLULARIS | SYSTEM PEPTIDES | NEUROSCIENCES | VASOPRESSIN RELEASE | RAT MODEL | CGP 42 | SMOOTH-MUSCLE | RECEPTOR SUBTYPES | ANTERIOR PRETECTAL NUCLEUS | 112A | INCISIONAL PAIN | Receptors, Angiotensin - metabolism | Analgesics - pharmacology | Pain Threshold - physiology | Rats, Wistar | Angiotensin Receptor Antagonists | Periaqueductal Gray - drug effects | Analgesics - metabolism | Male | Pain - metabolism | Efferent Pathways - drug effects | Neural Inhibition - physiology | Glutamyl Aminopeptidase - biosynthesis | Pain - drug therapy | Pain Threshold - drug effects | Disease Models, Animal | Angiotensin III - pharmacology | Angiotensin II - pharmacology | Microinjections | Losartan - pharmacology | Rats | Periaqueductal Gray - metabolism | Angiotensin III - metabolism | Efferent Pathways - metabolism | Peptides - pharmacology | Animals | Pain - physiopathology | Drug Interactions - physiology | Nociceptors - metabolism | Oligopeptides - pharmacology | Pain Measurement | Neural Inhibition - drug effects | Nociceptors - drug effects
Journal Article
Neuropeptides, ISSN 0143-4179, 2011, Volume 45, Issue 5, pp. 329 - 335
Abstract Angiotensin (Ang) III is a biologically active metabolite of Ang II with similar effects and receptor binding properties as Ang II. Most Ang III...
Endocrinology & Metabolism | Advanced Basic Science | Mitogen activated protein kinase | Angiotensin III | Angiotensin II | Astrocyte growth | C-FOS | PROLIFERATION | AMINOPEPTIDASES | IDENTIFICATION | NEUROSCIENCES | AT RECEPTORS | ENDOCRINOLOGY & METABOLISM | GENE-EXPRESSION | SMOOTH-MUSCLE-CELLS | DYSFUNCTION | HYPERTENSION | BRAIN | Phosphorylation | Cerebellum - drug effects | Astrocytes - enzymology | Cerebellum - enzymology | Angiotensin II Type 1 Receptor Blockers - pharmacology | Brain Stem - drug effects | Angiotensin II Type 2 Receptor Blockers - pharmacology | Brain Stem - enzymology | Flavonoids - pharmacology | Angiotensin III - pharmacology | Astrocytes - drug effects | Angiotensin II - pharmacology | Angiotensin II - metabolism | Cells, Cultured | Enzyme Inhibitors - pharmacology | Losartan - pharmacology | Rats | Imidazoles - pharmacology | Rats, Sprague-Dawley | Angiotensin III - metabolism | Animals | MAP Kinase Signaling System - drug effects | Mitogen-Activated Protein Kinases - antagonists & inhibitors | Pyridines - pharmacology | Mitogen-Activated Protein Kinases - metabolism | Physiological aspects | Metabolites | Growth | Protein kinases | Mitogens | Angiotensin | Cerebellum | Astrocytes | Brain stem | Extracellular signal-regulated kinase | MAP kinase | Neuropeptides | Signal transduction | Receptor mechanisms
Endocrinology & Metabolism | Advanced Basic Science | Mitogen activated protein kinase | Angiotensin III | Angiotensin II | Astrocyte growth | C-FOS | PROLIFERATION | AMINOPEPTIDASES | IDENTIFICATION | NEUROSCIENCES | AT RECEPTORS | ENDOCRINOLOGY & METABOLISM | GENE-EXPRESSION | SMOOTH-MUSCLE-CELLS | DYSFUNCTION | HYPERTENSION | BRAIN | Phosphorylation | Cerebellum - drug effects | Astrocytes - enzymology | Cerebellum - enzymology | Angiotensin II Type 1 Receptor Blockers - pharmacology | Brain Stem - drug effects | Angiotensin II Type 2 Receptor Blockers - pharmacology | Brain Stem - enzymology | Flavonoids - pharmacology | Angiotensin III - pharmacology | Astrocytes - drug effects | Angiotensin II - pharmacology | Angiotensin II - metabolism | Cells, Cultured | Enzyme Inhibitors - pharmacology | Losartan - pharmacology | Rats | Imidazoles - pharmacology | Rats, Sprague-Dawley | Angiotensin III - metabolism | Animals | MAP Kinase Signaling System - drug effects | Mitogen-Activated Protein Kinases - antagonists & inhibitors | Pyridines - pharmacology | Mitogen-Activated Protein Kinases - metabolism | Physiological aspects | Metabolites | Growth | Protein kinases | Mitogens | Angiotensin | Cerebellum | Astrocytes | Brain stem | Extracellular signal-regulated kinase | MAP kinase | Neuropeptides | Signal transduction | Receptor mechanisms
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 07/2008, Volume 588, Issue 2-3, pp. 286 - 293
Aminopeptidases metabolize angiotensin II to angiotensin-(2-8) (= angiotensin III) and angiotensin-(3-8) (= angiotensin IV), and carboxypeptidases generate...
Angiotensin AT | receptor | Mas receptor | Metabolite | Angiotensin | NG-Nitroarginine Methyl Ester - pharmacology | Angiotensin III - pharmacology | Receptor, Angiotensin, Type 2 - agonists | Angiotensin II - pharmacology | Coronary Vessels - drug effects | Angiotensin II - metabolism | Rats, Wistar | Coronary Vessels - physiology | Rats | Receptor, Angiotensin, Type 2 - drug effects | Male | Imidazoles - pharmacology | Angiotensin II - analogs & derivatives | Vasoconstriction - drug effects | Dose-Response Relationship, Drug | Animals | Ligands | Pyridines - pharmacology | In Vitro Techniques
Angiotensin AT | receptor | Mas receptor | Metabolite | Angiotensin | NG-Nitroarginine Methyl Ester - pharmacology | Angiotensin III - pharmacology | Receptor, Angiotensin, Type 2 - agonists | Angiotensin II - pharmacology | Coronary Vessels - drug effects | Angiotensin II - metabolism | Rats, Wistar | Coronary Vessels - physiology | Rats | Receptor, Angiotensin, Type 2 - drug effects | Male | Imidazoles - pharmacology | Angiotensin II - analogs & derivatives | Vasoconstriction - drug effects | Dose-Response Relationship, Drug | Animals | Ligands | Pyridines - pharmacology | In Vitro Techniques
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 10/1996, Volume 93, Issue 21, pp. 11968 - 11973
Angiotensin (Ang) II and Ang III are two peptide effectors of the brain renin-angiotensin system that participate in the control of blood pressure and increase...
Enzymes | Brain | Receptors | Thiols | Half lives | Hypothalamus | Radioactive decay | Metabolism | Assessors parcel numbers | Blood plasma | mouse | zinc metalloproteases | hypothalamus | renin-angiotensin system | mercapto-inhibitors | BESTATIN | MULTIDISCIPLINARY SCIENCES | BLOOD-PRESSURE | HYPERTENSIVE RAT | RESPONSES | PARAVENTRICULAR NUCLEUS | INDUCED DIPSOGENICITY | PRESSOR ACTIVITY | PITUITARY | AMASTATIN | GLUTAMYL AMINOPEPTIDASE | Amino Acid Sequence | Angiotensin III - pharmacology | Angiotensin II - pharmacology | Angiotensin II - administration & dosage | Angiotensin II - metabolism | Sulfhydryl Compounds - pharmacology | CD13 Antigens - antagonists & inhibitors | Injections, Intraventricular | Substrate Specificity | Male | Vasopressins - metabolism | Glutamyl Aminopeptidase | Aminopeptidases - antagonists & inhibitors | Cerebral Ventricles - drug effects | Sulfonic Acids - pharmacology | Angiotensin III - metabolism | Cerebral Ventricles - physiology | Protease Inhibitors - pharmacology | Saralasin - pharmacology | Animals | Time Factors | Angiotensin III - administration & dosage | Mice | Kinetics | Physiological aspects | Aminopeptidases | Vasopressin | Angiotensin
Enzymes | Brain | Receptors | Thiols | Half lives | Hypothalamus | Radioactive decay | Metabolism | Assessors parcel numbers | Blood plasma | mouse | zinc metalloproteases | hypothalamus | renin-angiotensin system | mercapto-inhibitors | BESTATIN | MULTIDISCIPLINARY SCIENCES | BLOOD-PRESSURE | HYPERTENSIVE RAT | RESPONSES | PARAVENTRICULAR NUCLEUS | INDUCED DIPSOGENICITY | PRESSOR ACTIVITY | PITUITARY | AMASTATIN | GLUTAMYL AMINOPEPTIDASE | Amino Acid Sequence | Angiotensin III - pharmacology | Angiotensin II - pharmacology | Angiotensin II - administration & dosage | Angiotensin II - metabolism | Sulfhydryl Compounds - pharmacology | CD13 Antigens - antagonists & inhibitors | Injections, Intraventricular | Substrate Specificity | Male | Vasopressins - metabolism | Glutamyl Aminopeptidase | Aminopeptidases - antagonists & inhibitors | Cerebral Ventricles - drug effects | Sulfonic Acids - pharmacology | Angiotensin III - metabolism | Cerebral Ventricles - physiology | Protease Inhibitors - pharmacology | Saralasin - pharmacology | Animals | Time Factors | Angiotensin III - administration & dosage | Mice | Kinetics | Physiological aspects | Aminopeptidases | Vasopressin | Angiotensin
Journal Article
Journal of the Renin-Angiotensin-Aldosterone System, ISSN 1470-3203, 12/2015, Volume 16, Issue 4, pp. 758 - 767
Introduction: Recently we established that pro-inflammatory actions of angiotensin (Ang) II in astrocytes involved Janus kinase 2 (JAK2), signal transducer and...
Proliferation | Angiotensin III | Astrocytes | Signal transducer and activator of transcription 3 | Interleukin-6 | SYSTEM | PROTEIN | proliferation | AT RECEPTOR | signal transducer and activator of transcription 3 | interleukin-6 | VASOPRESSIN RELEASE | BLOOD-PRESSURE | IN-VITRO | JAK/STAT PATHWAY | GROWTH | PERIPHERAL VASCULAR DISEASE | SMOOTH-MUSCLE-CELLS | astrocytes | BRAIN | Angiotensin III - pharmacology | Astrocytes - drug effects | Interleukin-6 - genetics | RNA, Messenger - genetics | Cells, Cultured | Losartan - pharmacology | Imidazoles - pharmacology | RNA, Messenger - metabolism | Rats, Sprague-Dawley | Gene Expression Regulation - drug effects | Animals | Time Factors | DNA - biosynthesis | Cyclic S-Oxides - pharmacology | Pyridines - pharmacology | Phosphorylation - drug effects | Interleukin-6 - metabolism | STAT3 Transcription Factor - metabolism | Astrocytes - metabolism
Proliferation | Angiotensin III | Astrocytes | Signal transducer and activator of transcription 3 | Interleukin-6 | SYSTEM | PROTEIN | proliferation | AT RECEPTOR | signal transducer and activator of transcription 3 | interleukin-6 | VASOPRESSIN RELEASE | BLOOD-PRESSURE | IN-VITRO | JAK/STAT PATHWAY | GROWTH | PERIPHERAL VASCULAR DISEASE | SMOOTH-MUSCLE-CELLS | astrocytes | BRAIN | Angiotensin III - pharmacology | Astrocytes - drug effects | Interleukin-6 - genetics | RNA, Messenger - genetics | Cells, Cultured | Losartan - pharmacology | Imidazoles - pharmacology | RNA, Messenger - metabolism | Rats, Sprague-Dawley | Gene Expression Regulation - drug effects | Animals | Time Factors | DNA - biosynthesis | Cyclic S-Oxides - pharmacology | Pyridines - pharmacology | Phosphorylation - drug effects | Interleukin-6 - metabolism | STAT3 Transcription Factor - metabolism | Astrocytes - metabolism
Journal Article
16.
Full Text
Roles of Coagulation and Fibrinolysis in Angiotensin II‐Enhanced Microvascular Thrombosis
Microcirculation, ISSN 1073-9688, 07/2014, Volume 21, Issue 5, pp. 401 - 407
Objective AngII‐induced HTN is associated with accelerated thrombus development in arterioles. This study assessed the contributions of different components of...
fibrinolysis | anticoagulants | thrombosis | coagulation | angiotensin II | Anticoagulants | Angiotensin II | Fibrinolysis | Thrombosis | Coagulation | RENOVASCULAR HYPERTENSIVE-RATS | RECEPTOR ANTAGONISTS | PLASMINOGEN-ACTIVATOR INHIBITOR-1 | PROTEIN-C | CONVERTING ENZYME-INHIBITION | ENDOTHELIAL-CELLS | ANTITHROMBIN-III | PERIPHERAL VASCULAR DISEASE | PROTHROMBOTIC STATE | PLATELET ACTIVATION | HEMATOLOGY | TISSUE FACTOR | Vasoconstrictor Agents - pharmacology | Fibrinolysis - drug effects | Thromboplastin - pharmacology | Angiotensin II - pharmacology | Microvessels - metabolism | Microvessels - pathology | Hemostatics - pharmacology | Male | Mice, Knockout | Antithrombins - pharmacology | Thrombosis - pathology | Antithrombin III - pharmacology | Serpin E2 - genetics |
fibrinolysis | anticoagulants | thrombosis | coagulation | angiotensin II | Anticoagulants | Angiotensin II | Fibrinolysis | Thrombosis | Coagulation | RENOVASCULAR HYPERTENSIVE-RATS | RECEPTOR ANTAGONISTS | PLASMINOGEN-ACTIVATOR INHIBITOR-1 | PROTEIN-C | CONVERTING ENZYME-INHIBITION | ENDOTHELIAL-CELLS | ANTITHROMBIN-III | PERIPHERAL VASCULAR DISEASE | PROTHROMBOTIC STATE | PLATELET ACTIVATION | HEMATOLOGY | TISSUE FACTOR | Vasoconstrictor Agents - pharmacology | Fibrinolysis - drug effects | Thromboplastin - pharmacology | Angiotensin II - pharmacology | Microvessels - metabolism | Microvessels - pathology | Hemostatics - pharmacology | Male | Mice, Knockout | Antithrombins - pharmacology | Thrombosis - pathology | Antithrombin III - pharmacology | Serpin E2 - genetics |